Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

This Phase 1 trial tests a new drug called UCMYM802 — an antibody-drug conjugate (a targeted missile that delivers chemotherapy directly to cancer cells) — in patients with solid tumors that express a protein called mesothelin. Mesothelin is found on the surface of certain cancers including mesothelioma, pancreatic, lung, and ovarian cancer. This early-stage trial mainly assesses safety and dosing. **You may be eligible if...** - You are aged 18–70 with a confirmed solid tumor that tests positive for mesothelin - Your cancer has not responded to or you cannot tolerate standard treatments - You have at least one evaluable tumor on imaging - You can provide a tumor tissue sample (or agree to a biopsy) - Your overall health is adequate (good organ function, acceptable blood counts) **You may NOT be eligible if...** - Your tumor does not express mesothelin - You have active serious infections or other conditions making treatment unsafe - You have had prior treatments that would overlap with this drug - Your organ function is below the study's thresholds Talk to your doctor to see if this trial is right for you.